Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001423029-25-000003

Chief Executive Officer sold 184,298 shares at an average $67.00 ($12,348,802)

  • Chief Executive Officer acquired 180,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Anzalone Christopher Richard · Chief Executive Officer

Table I: Non-derivative

13 lines
Date Transaction Shares Price Value Owned after D/I
2025-12-12 Grant or award : show line 1 in the form +180,000 4,101,255 D
2025-12-15 Sale : show line 2 in the form −100,532 $68.67 $6,903,532 4,000,723 D
2025-12-15 Sale : show line 3 in the form −21,321 $69.28 $1,477,119 3,979,402 D
2025-12-15 Sale : show line 4 in the form −8,147 $69.96 $569,964 3,971,255 D
2025-12-16 Sale : show line 5 in the form −8,416 $60.51 $509,252 3,962,839 D
2025-12-16 Sale : show line 6 in the form −10,963 $61.25 $671,484 3,951,876 D
2025-12-16 Sale : show line 7 in the form −14,095 $62.12 $875,581 3,937,781 D
2025-12-16 Sale : show line 8 in the form −8,476 $62.94 $533,479 3,929,305 D
Open-market sales · 184,298 sh · avg $67.00 · $12,348,802
Loading xslF345X05/wk-form4_1765908884.xml…